Results 271 to 280 of about 162,494 (358)

Association of Omeprazole‐Related Myopathy With Drug–Drug and Drug–Gene Interactions Involving CYP2C19 and CYP3A4: A Nested Case–Control Study

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 45, Issue 10, Page 654-666, October 2025.
ABSTRACT Background Omeprazole, a widely used proton pump inhibitor, has been associated with rare but serious adverse events such as myopathy. Previous research suggests that concurrent use of omeprazole with fluconazole, a potent cytochrome P450 (CYP) 2C19/3A4 inhibitor, may increase the risk of myopathy.
Eugene Jeong, Aditi Shendre, Yu Su, Xingyi Guo, Lang Li, You Chen   +5 more
wiley   +1 more source

Evaluation of the treatment patterns among commercially insured patients with nonvalvular atrial fibrillation prescribed an oral anticoagulant by race/ethnicity. [PDF]

J Comp Eff Res
Zhang M, Singh R, Dhuliawala S, Stafkey D, Vodicka E, Cheng D, Dubey A, Hagan M.   +7 more
europepmc   +1 more source

Studies on the variation in Factor X activity in patients given warfarin according to the assay methods

, 1980
M Nasu, Y Izumiguchi, Hiroshi Hara, Eizo Kakishita   +3 more
openalex   +2 more sources

Development and Verification of Virtual Population Models for Predicting Drug Pharmacokinetics in Ethnic North American Populations

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 10, Page 1598-1615, October 2025.
ABSTRACT Ethnic variabilities can affect the outcome of drug pharmacokinetics (PK) and drug–drug interactions (DDI). This work aimed to develop four North American (NA) sub‐populations: White, African American, Asian American, and Hispanic_Latino suitable for physiologically based pharmacokinetic (PBPK) modeling and simulations.
Udoamaka Ezuruike, Jean Dinh, Eman El‐Khateeb, Alex Blenkinsop, Oliver Hatley, Iain Gardner   +5 more
wiley   +1 more source

Direct oral anticoagulants in very elderly and high-bleeding-risk patients with atrial fibrillation often excluded from oral anticoagulation therapy: a nationwide population-based cohort study. [PDF]

Europace
Go YH, Lee SR, Lee SR, Choi EK, Ahn HJ, Han KD, Oh S, Lip GYH.   +7 more
europepmc   +1 more source

Warfarin therapy for navicular disease

, 1980

openalex   +1 more source

Assessing Cytochrome P450 Drug Interaction Risk for Dordaviprone Using Physiologically Based Pharmacokinetic Modeling

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 10, Page 1695-1704, October 2025.
ABSTRACT A physiologically based pharmacokinetic (PBPK) model was developed and verified for dordaviprone, a small molecule with antitumor effects in glioma patients. The model was applied to assess the drug–drug interaction (DDI) potential of dordaviprone as a victim of CYP3A4 inhibitors and inducers, and as a perpetrator of CYP3A4, CYP2C8, CYP2D6 ...
Swati Jaiswal, Nikunjkumar K. Patel, Hannah M. Jones, Savannah McFeely, Shamia L. Faison, Tim Tippin, Odin Naderer   +6 more
wiley   +1 more source

Silent Dangers in Elderly Pharmacotherapy: The Interplay of Polypharmacy, Multimorbidity, and Drug Interactions. [PDF]

J Eval Clin Pract
Ngcobo NN.
europepmc   +1 more source

The prophylactic effect of warfarin and aspirin in cerebral ischemia

, 1981
Hiroshi Yamanouchi, Hideo Tohgi, Hiroshi Nagura, Toshio Fukazawa, Tamotsu Matsuda   +4 more
openalex   +2 more sources

Platelet‐Macrophage Aggregates in Remodeled Vessels of Patients With Pulmonary Arterial Hypertension

Pulmonary Circulation, Volume 15, Issue 4, October 2025.
ABSTRACT Using lung immunohistochemistry and stereology, platelets were found to accumulate and co‐localize with leukocytes, particularly monocytes, within the mural and adventitial space of remodeled vessels of patients with pulmonary arterial hypertension.
Christine L. Farrell, Mariah Jordan, Janelle N. Posey, Kimberly R. Jordan, Aneta Gandjeva, Eva S. Nozik, Kurt R. Stenmark, Rubin M. Tuder, Brian B. Graham, Cassidy A. Delaney   +9 more
wiley   +1 more source